UCF Study Suggests Alzheimer’s Mutations May Impair Motor Function

Researchers at the University of Central Florida have identified that genetic mutations associated with familial Alzheimer’s disease can directly impair nerve-to-muscle communication outside the brain and spinal cord.

The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, suggests that motor deficits may serve as early indicators of the disease before cognitive symptoms appear.

Key Clinical Takeaways:

• Familial Alzheimer’s mutations can disrupt neuromuscular junctions independently of brain or spinal cord degeneration.
• Laboratory models using “human-on-a-chip” technology demonstrate that peripheral nerve cells fail to communicate effectively with muscle tissue when carrying these mutations.
• Early detection of gait or coordination changes may provide a new window for clinical intervention before central nervous system decline accelerates.

Alzheimer’s disease is traditionally categorized by progressive cognitive decline, yet clinicians have long noted that patients often exhibit motor symptoms—such as gait instability and impaired coordination—years before memory loss becomes severe.

The research team, led by James Hickman of the University of Central Florida’s Nanoscience Technology Center and Research Professor Xiufang “Nadine” Guo, sought to determine if these physical symptoms were merely secondary to brain damage or if the disease directly impacts the peripheral nervous system.

The study utilized laboratory systems developed by Hesperos to isolate neuromuscular junctions. By engineering these systems without the presence of a brain or spinal cord, the researchers observed that motor neurons carrying familial Alzheimer’s mutations failed to trigger muscle contractions as effectively as healthy cells.

“This is the first time it’s been demonstrated that deficits in the peripheral nervous system can arise directly from these mutations,” Hickman stated. He noted that this finding implies current therapeutic strategies targeting only the brain may fail to address systemic physiological decline.

The investigation was funded by the National Institutes of Health’s National Institute on Aging. To bypass the limitations of animal models, which often fail to replicate human-specific pathology, the team used “human-on-a-chip” technology.

This platform allowed scientists to combine stem-cell-derived motor neurons with healthy muscle tissue in a controlled environment. By measuring the electrical signals and chemical responses at the neuromuscular junction, the team established that the mutations directly interfere with signal transmission.

Guo says early intervention could be highly effective. “Motor deficits may be an earlier indication,” Guo said.

While the study focused on familial Alzheimer’s—a rare, early-onset form of the disease—the findings raise questions about whether similar mechanisms exist in more common, late-onset cases. Further longitudinal research is required to determine how these neuromuscular changes correlate with the timeline of cognitive decline in broader patient populations.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.